A blockbuster year could be building
If forecasts prove accurate 2023 could be the biggest year for blockbuster launches for some time.
The sellside hacks back Lynparza’s prostate opportunity
The writing had been on the wall for Parp inhibitors in first-line prostate cancer, and last week’s US panel showed no mercy.
